Gene · 2804
Papers1,684
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,684
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. | Theranostics | 2023 | 37056572 | PubTator, text mining | PubMed |
| Role of GARP Vesicle Tethering Complex in Golgi Physiology. | Int J Mol Sci | 2023 | 37047041 | PubTator, text mining | PubMed |
| Golgi-Targeting Anticancer Natural Products. | Cancers (Basel) | 2023 | 37046746 | PubTator, text mining | PubMed |
| Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma. | Oncogene | 2023 | 37046045 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial. | Trials | 2023 | 37016392 | PubTator, text mining | PubMed |
| Reproducibility challenges in robotic surgery. | Front Robot AI | 2023 | 37008982 | PubTator, text mining | PubMed |
Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania. | Pilot Feasibility Stud | 2023 | 37005695 | PubTator, text mining | PubMed |
| BISCIT: Biliary interventions in critically ill patients with secondary sclerosing cholangitis-a study protocol for a multicenter, randomized, controlled parallel group trial. | Trials | 2023 | 37004078 | PubTator, text mining | PubMed |
| The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study. | Cancer Med | 2023 | 36999931 | PubTator, text mining | PubMed |
| Methods of GCP ability training for residents. | Asian J Surg | 2023 | 36990818 | PubTator, text mining | PubMed |
| Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study. | Trials | 2023 | 36966349 | PubTator, text mining | PubMed |
| Effect of lung ultrasound-guided fluid deresuscitation on duration of ventilation in intensive care unit patients (CONFIDENCE): protocol for a multicentre randomised controlled trial. | Trials | 2023 | 36964614 | PubTator, text mining | PubMed |
| Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial). | BMC Cancer | 2023 | 36959540 | PubTator, text mining | PubMed |
| A central chaperone-like role for 14-3-3 proteins in human cells. | Mol Cell | 2023 | 36931259 | PubTator, text mining | PubMed |
| PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V). | Trials | 2023 | 36915199 | PubTator, text mining | PubMed |
| Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021). | Hum Vaccin Immunother | 2023 | 36896702 | PubTator, text mining | PubMed |
| The function of Golgi apparatus in LRRK2-associated Parkinson's disease. | Front Mol Neurosci | 2023 | 36896008 | PubTator, text mining | PubMed |
| International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. | Global Health | 2023 | 36869318 | PubTator, text mining | PubMed |
| MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey. | J Transl Med | 2023 | 36864416 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2804/papers?page=9